A feed for enhancing immunity of tilapia and preparation method thereof, wherein the feed includes 20-30 parts of rice chaff, 15-25 parts of earthworm powder, 10-15 parts of shrimp shell powder, 10-15 parts of sodium alginate, 5-10 parts of oyster shell powder, 5-10 parts of cyclohexanone, 10-15 parts of honeysuckle extract, 3-5 parts of Commelina communis extract, 3-6 parts of β-1,3-glucan, 2-3 parts of flavomycin growth promoter, 1-3 parts of complex enzyme preparation, 5-8 parts of selenium methionine, 6-10 parts of distiller's grains, 1-3 parts of complex vitamins, 1-3 parts of complex trace elements and 2-3 parts of food attractant, in parts by weight.

The present invention relates to compounds with high chemical stability and methods for inhibiting the pathological activity of extracellular histones in a subject. In particular, the invention relates to compounds with high chemical stability, uses thereof and methods for inhibiting or ameliorating extracellular histone mediated ailments (such as, for example, sepsis, systemic immune response syndrome (SIRS) and ischemia reperfusion injury (IRO). More particularly, the invention relates to methods and uses of a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus, wherein the presence of the substituent results in a molecule with high chemical stability without affecting the ability of the molecule to be effective in the therapy of extracellular histone mediated ailments. For example, the present invention relates to methods and uses of β-O-methyl cellobioside sulfate (mCBS) or a pharmaceutically acceptable salt thereof (e.g., mCBS.Math.Na), in the therapy of a range of extracellular histone mediated ailments in subjects.

The present invention relates to compounds with high chemical stability and methods for inhibiting the pathological activity of extracellular histones in a subject. In particular, the invention relates to compounds with high chemical stability, uses thereof and methods for inhibiting or ameliorating extracellular histone mediated ailments (such as, for example, sepsis, systemic immune response syndrome (SIRS) and ischemia reperfusion injury (IRO). More particularly, the invention relates to methods and uses of a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus, wherein the presence of the substituent results in a molecule with high chemical stability without affecting the ability of the molecule to be effective in the therapy of extracellular histone mediated ailments. For example, the present invention relates to methods and uses of β-O-methyl cellobioside sulfate (mCBS) or a pharmaceutically acceptable salt thereof (e.g., mCBS.Math.Na), in the therapy of a range of extracellular histone mediated ailments in subjects.

The present invention relates to the use of carotenoids, in particular a microbial carotenoid compound of formula I, such as methyl-glycosyl-apo-8′-lycopenoate or glycosyl-apo-8′-lycopene, for restoring and/or maintaining a health-beneficial gut microbial composition in a subject. The invention further provides the use of said compound in the treatment of disorders associated with a disturbed intestinal barrier integrity, such as for example irritable bowel syndrome. Further, a compound or composition comprising a microbial carotenoid compound is disclosed for use in the prevention and/or treatment of disorders associated with disturbed intestinal barrier integrity.

The present invention relates to the use of carotenoids, in particular a microbial carotenoid compound of formula I, such as methyl-glycosyl-apo-8′-lycopenoate or glycosyl-apo-8′-lycopene, for restoring and/or maintaining a health-beneficial gut microbial composition in a subject. The invention further provides the use of said compound in the treatment of disorders associated with a disturbed intestinal barrier integrity, such as for example irritable bowel syndrome. Further, a compound or composition comprising a microbial carotenoid compound is disclosed for use in the prevention and/or treatment of disorders associated with disturbed intestinal barrier integrity.

The application disclosure provides a sterically stabilized liposome carrier encapsulating a selected drug for the aerosol delivery of the drug effectual in the treatment of a mammal, a composition containing the sterically stabilized liposome carrier and the selected drug effective for the treatment of airway hypersensitivity and inflammation such as of the lungs of a mammal as an aerosol, and a method of treatment using the composition. The composition disclosed herein provides effective treatment for the longer of a period of time at least twice as long as the selected drug alone or up to at least one week.

The application disclosure provides a sterically stabilized liposome carrier encapsulating a selected drug for the aerosol delivery of the drug effectual in the treatment of a mammal, a composition containing the sterically stabilized liposome carrier and the selected drug effective for the treatment of airway hypersensitivity and inflammation such as of the lungs of a mammal as an aerosol, and a method of treatment using the composition. The composition disclosed herein provides effective treatment for the longer of a period of time at least twice as long as the selected drug alone or up to at least one week.

The present invention relates to compounds useful for the treatment or prevention of bacteria infections. These compounds have formula I:

##STR00001##

The invention also provides pharmaceutically acceptable compositions containing the compounds and methods of using the compositions in the treatment of bacteria infections. Finally, the invention provides processes for making compounds of the invention.

The present invention relates to compounds useful for the treatment or prevention of bacteria infections. These compounds have formula I:

##STR00001##

The invention also provides pharmaceutically acceptable compositions containing the compounds and methods of using the compositions in the treatment of bacteria infections. Finally, the invention provides processes for making compounds of the invention.

The invention provides a substantially antigen-free composition for induction of innate immune response in a bird or a mammal, the composition comprising a saponin, a sterol, a quaternary amine, and a polyacrylic polymer to the mammal or bird. Methods of using the composition are also provided.